Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Brand Image Still Hinders Acceptance of GE Drugs: PJ, So-net M3 Survey
January 19, 2004
- FY 2004 Business Plan Approved: JPMA General Assembly
January 19, 2004
- BUSINESS NEWS IN BRIEF
January 19, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
January 19, 2004
- AstraZeneca Integrates R&D in Japan into AZ Global Development
January 19, 2004
- WEBSITE NEWS
January 19, 2004
- 1 in 3 Glaucoma Patients Has Poor Compliance: Patient Body Survey
January 19, 2004
- Expecting Better Allocation of Medical Fees in FY2004: Health Minister
January 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
January 19, 2004
- Dr Sakaguchi Appeals for Steps to Prevent Medical Accidents
January 19, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 19, 2004
- Korosho to Establish System to More Quickly Approve New Indications: PFSB DG
January 19, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 19, 2004
- Korosho to Approve Additional Indications for More Anti-cancer Drugs
January 19, 2004
- OTC NEWS IN BRIEF
January 19, 2004
- Chuikyo to Resume Discussions on 80% Rule for 1st Generics
January 19, 2004
- Meet the Leaders (29)
January 19, 2004
- Korosho Rejects Requests for Expanded Participation in Structural Reform Zones
January 19, 2004
- Takeda's Blopress Aims for 40% Share in ARB Market
January 19, 2004
- Births Down 3rd Year in a Row, Hit Historic Low in 2003: Vital Statistics
January 19, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…